Form 4: Cytokinetics Executive Exercises Options, Sells Shares
Insider Transaction Report
Cytokinetics EVP and Chief Commercial Officer Andrew Callos exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.
Summary
- Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc. (CYTK), engaged in an insider transaction on December 8, 2025.
- Callos exercised non-qualified stock options to acquire 1,042 shares of common stock at an exercise price of $39.13 per share.
- Concurrently, Callos sold 1,042 shares of common stock at a price of $65.96 per share.
- The transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
- Following these transactions, Callos directly beneficially owns 50,660 shares of common stock and 35,403 derivative securities (non-qualified stock options).
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While an executive sale can sometimes be viewed negatively, the transaction was pre-planned under Rule 10b5-1, mitigating concerns. The executive also realized a significant gain from the option exercise and sale.
Positives
- The executive realized a gain by selling shares at $65.96, significantly higher than the exercise price of $39.13.
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned and structured approach to managing equity, which can reduce concerns about opportunistic insider trading.
Negatives
- An executive selling shares, even if pre-planned, can sometimes be interpreted by the market as a signal, though this is often a routine liquidity event or part of tax planning.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 12/08/2025 | Indicates adherence to pre-arranged trading plans, which are designed to prevent insider trading based on material non-public information. |
Stakeholder Impact
- Shareholders may note the executive's decision to sell shares, which could be interpreted in various ways depending on individual investment strategies and market sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/06/2023 | Date the non-qualified stock options became exercisable. |
| 12/08/2025 | Date of the option exercise and subsequent sale of common stock. |
| 03/06/2033 | Expiration date of the non-qualified stock options. |
Keywords
CYTOKINETICS, CYTK, Form 4, insider trading, stock options, executive compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.